Reata Pharmaceuticals, Inc. – NASDAQ:RETA
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Reata Pharmaceuticals stock price monthly change
+1.99%
month
Reata Pharmaceuticals stock price quarterly change
+85.03%
quarter
Reata Pharmaceuticals stock price yearly change
+679.20%
year
Reata Pharmaceuticals key metrics
Market Cap | 6.56B |
Enterprise value | 3.58B |
P/E | -11.15 |
EV/Sales | 1145.38 |
EV/EBITDA | -12.80 |
Price/Sales | 1120.73 |
Price/Book | -53.39 |
PEG ratio | 2.28 |
EPS | -2.33 |
Revenue | 24.39M |
EBITDA | -332.65M |
Income | -80.05M |
Revenue Q/Q | 2885.03% |
Revenue Y/Y | 143.92% |
Profit margin | -9964.89% |
Oper. margin | -6342.2% |
Gross margin | 24.35% |
EBIT margin | -6342.2% |
EBITDA margin | -1363.6% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeReata Pharmaceuticals stock price history
Reata Pharmaceuticals stock forecast
Reata Pharmaceuticals financial statements
| Sep 2022 | 540K | -76.79M | -14220.56% |
|---|---|---|---|
| Dec 2022 | 914K | -85.50M | -9354.7% |
| Mar 2023 | 195K | -110.76M | -56801.03% |
| Jun 2023 | 22.74M | 192.99M | 848.49% |
| Sep 2022 | 583644000 | 579.12M | 99.23% |
|---|---|---|---|
| Dec 2022 | 514491000 | 580.18M | 112.77% |
| Mar 2023 | 453582000 | 584.25M | 128.81% |
| Jun 2023 | 502587000 | 415.29M | 82.63% |
| Sep 2022 | -46.53M | -69.13M | 436K |
|---|---|---|---|
| Dec 2022 | -50.42M | 60.50M | 314K |
| Mar 2023 | -81.44M | 110.99M | 13.08M |
| Jun 2023 | -69.92M | -42.94M | 76.77M |
Reata Pharmaceuticals alternative data
| Aug 2023 | 321 |
|---|---|
| Sep 2023 | 321 |
| Oct 2023 | 321 |
| Nov 2023 | 321 |
| Dec 2023 | 321 |
| Jan 2024 | 321 |
| Feb 2024 | 321 |
| Mar 2024 | 321 |
| Apr 2024 | 321 |
| May 2024 | 321 |
| Jun 2024 | 321 |
| Jul 2024 | 321 |
Reata Pharmaceuticals other data
70.89%
-4.80%
of RETA is owned by hedge funds
137
+1
25.85M
-1.64M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2023 | 0 | 200578 |
| May 2023 | 0 | 9738 |
| Jun 2023 | 0 | 85139 |
| Jul 2023 | 0 | 128235 |
| Aug 2023 | 0 | 7308 |
| Sep 2023 | 0 | 406 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | ANAND BHASKAR officer: SVP, Chief Accounting .. | Class A common stock | 406 | $169.2 | $68,695 | ||
Sale | WORTLEY MICHAEL D officer: Chief Le.. | Class A common stock | 398 | $168.76 | $67,167 | ||
Sale | SONI MANMEET SINGH officer: COO, CFO.. | Class A common stock | 1,755 | $168.41 | $295,567 | ||
Sale | MEYER COLIN JOHN officer: Chief In.. | Class A common stock | 596 | $168.74 | $100,569 | ||
Sale | BIR DAWN CARTER officer: Chief Co.. | Class A common stock | 398 | $168.33 | $66,996 | ||
Sale | ANAND BHASKAR officer: SVP, Chief Accounting .. | Class A common stock | 210 | $168.42 | $35,368 | ||
Sale | WORTLEY MICHAEL D officer: Chief Le.. | Class A common stock | 807 | $169.04 | $136,414 | ||
Sale | MEYER COLIN JOHN officer: Chief In.. | Class A common stock | 2,144 | $169.07 | $362,484 | ||
Sale | BIR DAWN CARTER officer: Chief Co.. | Class A common stock | 807 | $169.04 | $136,413 | ||
Sale | ANAND BHASKAR officer: SVP, Chief Accounting .. | Class A common stock | 193 | $169.06 | $32,628 |
| Patent |
|---|
Grant Filling date: 5 Jun 2020 Issue date: 2 Aug 2022 |
Application Filling date: 18 Jan 2022 Issue date: 5 May 2022 |
Grant Filling date: 16 Dec 2017 Issue date: 5 Apr 2022 |
Application ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 Filling date: 9 Jul 2021 Issue date: 27 Jan 2022 |
Grant Filling date: 3 Dec 2019 Issue date: 7 Dec 2021 |
Application 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF Filling date: 25 Jun 2021 Issue date: 18 Nov 2021 |
Application Filling date: 17 Jun 2019 Issue date: 23 Sep 2021 |
Application BIARYL AMIDES WITH MODIFIED SUGAR GROUPS FOR TREATMENT OF DISEASES ASSOCIATED WITH HEAT SHOCK PROTEIN PATHWAY Filling date: 14 May 2019 Issue date: 26 Aug 2021 |
Grant Utility: Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 Filling date: 10 Feb 2020 Issue date: 17 Aug 2021 |
Grant Utility: 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof Filling date: 14 Jun 2017 Issue date: 3 Aug 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2023 11 May 2023 | Q1 2023 Earnings Call Transcript |
| Q3 2022 8 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 8 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 10 May 2022 | Q1 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Manmeet Singh Soni (1978) Chief Operating Officer, Chief Financial Officer & Executive Vice President | $1,130,000 |
Mr. J. Warren Huff (1954) Chairman, Chief Executive Officer & Pres | $1,060,000 |
| Dr. Colin J. Meyer (1979) Executive Vice President and Chief R&D Officer | $895,350 |
| Mr. Michael D. Wortley (1948) Executive Vice President & Chief Legal Officer | $760,600 |
| Ms. Dawn Carter Bir (1971) Executive Vice President & Chief Commercial Officer | $666,900 |
Reata: FDA Approval Of SKYCLARYS Isn't Only Driver Moving Forward
Reata Pharmaceuticals: 'Buy' Following Skyclarys Delay And Bardoxolone Discontinuation (Rating Upgrade)
Reata Pharmaceuticals: Still A Buy After Skyclarys Approval Jump
Biopharma Exposure In SVB Financial Group And Investor Strategy
Reata Pharmaceuticals: The Silver Bullet For Friedreich's Ataxia
Reata Pharmaceuticals: Binary Catalyst Unlocking
Reata Pharmaceuticals: Buy While Preparing For First Commercial Launch
DiaMedica: Proven Stroke Drug In Asia, Headed To The U.S.
Reata Pharmaceuticals: Finally, We Have A PDUFA
-
When is Reata Pharmaceuticals's next earnings date?
Unfortunately, Reata Pharmaceuticals's (RETA) next earnings date is currently unknown.
-
Does Reata Pharmaceuticals pay dividends?
No, Reata Pharmaceuticals does not pay dividends.
-
How much money does Reata Pharmaceuticals make?
Reata Pharmaceuticals has a market capitalization of 6.56B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 80.71% to 2.22M US dollars.
-
What is Reata Pharmaceuticals's stock symbol?
Reata Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "RETA".
-
What is Reata Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Reata Pharmaceuticals?
Shares of Reata Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Reata Pharmaceuticals's key executives?
Reata Pharmaceuticals's management team includes the following people:
- Mr. Manmeet Singh Soni Chief Operating Officer, Chief Financial Officer & Executive Vice President(age: 47, pay: $1,130,000)
- Mr. J. Warren Huff Chairman, Chief Executive Officer & Pres(age: 71, pay: $1,060,000)
- Dr. Colin J. Meyer Executive Vice President and Chief R&D Officer(age: 46, pay: $895,350)
- Mr. Michael D. Wortley Executive Vice President & Chief Legal Officer(age: 77, pay: $760,600)
- Ms. Dawn Carter Bir Executive Vice President & Chief Commercial Officer(age: 54, pay: $666,900)
-
How many employees does Reata Pharmaceuticals have?
As Jul 2024, Reata Pharmaceuticals employs 321 workers.
-
When Reata Pharmaceuticals went public?
Reata Pharmaceuticals, Inc. is publicly traded company for more then 9 years since IPO on 26 May 2016.
-
What is Reata Pharmaceuticals's official website?
The official website for Reata Pharmaceuticals is reatapharma.com.
-
Where are Reata Pharmaceuticals's headquarters?
Reata Pharmaceuticals is headquartered at 5320 Legacy Drive, Plano, TX.
-
How can i contact Reata Pharmaceuticals?
Reata Pharmaceuticals's mailing address is 5320 Legacy Drive, Plano, TX and company can be reached via phone at +972 8652219.
Reata Pharmaceuticals company profile:
Reata Pharmaceuticals, Inc.
reatapharma.comExchange:
NASDAQ
Full time employees:
321
Industry:
Biotechnology
Sector:
Healthcare
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
5320 Legacy Drive
Plano, TX 75024
Plano, TX 75024
CIK: 0001358762
ISIN: US75615P1030
CUSIP: 75615P103
